Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 10;4(1):e329.
doi: 10.1097/HS9.0000000000000329. eCollection 2020 Feb.

Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group

Stephen Daw  1 , Dirk Hasenclever  2 , Maurizio Mascarin  3 , Ana Fernández-Teijeiro  4 , Walentyna Balwierz  5 , Auke Beishuizen  6 , Roberta Burnelli  7 , Michaela Cepelova  8 , Alexander Claviez  9 , Karin Dieckmann  10 , Judith Landman-Parker  11 , Regine Kluge  12 , Dieter Körholz  13 , Christine Mauz-Körholz  13 , William Hamish Wallace  14 , Thierry Leblanc  15
Affiliations
Review

Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group

Stephen Daw et al. Hemasphere. .

Abstract

The objective of this guideline is to aid clinicians in making individual salvage treatment plans for pediatric and adolescent patients with first relapse or refractory (R/R) classical Hodgkin lymphoma (cHL). While salvage with standard dose chemotherapy followed by high dose chemotherapy and autologous stem cell transplant is often considered the standard of care in adult practice, pediatric practice adopts a more individualized risk stratified and response adapted approach to salvage treatment with greater use of non-transplant salvage. Here, we present on behalf of the EuroNet Pediatric Hodgkin Lymphoma group, evidence and consensus-based guidelines for standardized diagnostic, prognostic and response procedures to allocate children and adolescents with R/R cHL to stratified salvage treatments.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Summary of Treatment strategies. ASCT = autologous stem cell transplant, CMR = complete metabolic remission, DS = Deauville score, HDCT = high dose chemotherapy, IFRT = involved filed radiotherapy, SDCT = standard dose chemotherapy. ∗see text for further discussion.
None
None
See this image and copyright information in PMC

References

    1. Dörffel W, Luders H, Ruhl U, et al. Preliminary results of the multi-center trial GPOH-HD-95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klinische Padiatrie. 2003;215:139–145. - PubMed
    1. Mauz-Korholz C, Hasenclever D, Dorffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010;28:3680–3686. - PubMed
    1. Tebbi CK, Mendenhall NP, London WB, et al. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012;59:1259–1265. - PMC - PubMed
    1. Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114:2051–2059. - PMC - PubMed
    1. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with ABMT in relapsed and resistant Hodgkin's disease, results of a BNLI randomised trial. Lancet. 1993;341:1051–1054. - PubMed